Q&A: Former CDRH Director Dan Schultz On Communication Issues, 510(k)s
This article was originally published in The Gray Sheet
Executive Summary
For former FDA device center director Dan Schultz, his new job since leaving the agency may feel a bit familiar: explaining FDA's sometimes convoluted processes to frustrated device firms
You may also be interested in...
Schultz Exits: Pressures From Inside And Out Catch Up With CDRH Director
At least a handful of disgruntled employees, members of Congress champing at the bit and a new reformist FDA administration were apparently the undoing of Dan Schultz's leadership of CDRH
FDA Can’t Inspect Its Way Out Of Import Safety Problems – Schultz, Sharfstein
Increasing the number of foreign device facility inspections alone will not dramatically improve FDA import safety, agency leaders say
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.